Literature DB >> 26132003

Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Vaithamanithi-Mudumbai Sadagopa Ramanujam1, Karl Elmo Anderson1,2.   

Abstract

Porphyria diseases are a group of metabolic disorders caused by abnormal functioning of heme biosynthesis enzymes and characterized by excessive accumulation and excretion of porphyrins and their precursors. Precisely which of these chemicals builds up depends on the type of porphyria. Porphyria is not a single disease but a group of nine disorders: acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), variegate porphyria (VP), δ-aminolevulinic acid dehydratase deficiency porphyria (ADP), porphyria cutanea tarda (PCT), hepatoerythropoietic porphyria (HEP), congenital erythropoietic porphyria (CEP), erythropoietic protoporphyria (EPP), and X-linked protoporphyria (XLP). Each porphyria results from overproduction of heme precursors secondary to partial deficiency or, in XLP, increased activity of one of the enzymes of heme biosynthesis. Taken together, all forms of porphyria afflict fewer than 200,000 people in the United States. Based on European studies, the most common porphyria, PCT, has a prevalence of 1 in 10,000, the most common acute porphyria, AlP, has a prevalence of ∼1 in 20,000, and the most common erythropoietic porphyria, EPP, is estimated at 1 in 50,000 to 75,000. CEP is extremely rare, with prevalence estimates of 1 in 1,000,000 or less. Only six cases of ADP are documented. The current porphyria literature is very exhaustive and a brief overview of porphyria diseases is essential in order for the reader to better appreciate the relevance of this area of research prior to undertaking biochemical diagnostics procedures. This unit summarizes the current knowledge on the classification, clinical features, etiology, pathogenesis, and genetics of porphyria diseases.
Copyright © 2015 John Wiley & Sons, Inc.

Entities:  

Keywords:  Porphyria; clinical features; etiology; overview; pathogenesis

Mesh:

Year:  2015        PMID: 26132003      PMCID: PMC4640448          DOI: 10.1002/0471142905.hg1720s86

Source DB:  PubMed          Journal:  Curr Protoc Hum Genet        ISSN: 1934-8258


  212 in total

Review 1.  Congenital erythropoietic porphyria: advances in pathogenesis and treatment.

Authors:  Robert J Desnick; Kenneth H Astrin
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

2.  Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. Report of 348 cases caused by this fungicide.

Authors:  C CAN; G NIGOGOSYAN
Journal:  JAMA       Date:  1963-01-12       Impact factor: 56.272

3.  Fifty years of porphyria at the University of Cape Town.

Authors:  Peter N Meissner; Anne V Corrigall; Richard J Hift
Journal:  S Afr Med J       Date:  2012-03-02

Review 4.  Pathophysiology of cutaneous lesions in porphyrias.

Authors:  H W Lim
Journal:  Semin Hematol       Date:  1989-04       Impact factor: 3.851

5.  Ferrochelatase activities in patients with erythropoietic protoporphyria and their families.

Authors:  G Goerz; S Bunselmeyer; K Bolsen; N Y Schürer
Journal:  Br J Dermatol       Date:  1996-05       Impact factor: 9.302

6.  Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update.

Authors:  R Rosipal; J Lamoril; H Puy; V Da Silva; L Gouya; F W De Rooij; K Te Velde; Y Nordmann; P Martàsek; J C Deybach
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

7.  Afamelanotide for Erythropoietic Protoporphyria.

Authors:  Janneke G Langendonk; Manisha Balwani; Karl E Anderson; Herbert L Bonkovsky; Alexander V Anstey; D Montgomery Bissell; Joseph Bloomer; Chris Edwards; Norbert J Neumann; Charles Parker; John D Phillips; Henry W Lim; Iltefat Hamzavi; Jean-Charles Deybach; Raili Kauppinen; Lesley E Rhodes; Jorge Frank; Gillian M Murphy; Francois P J Karstens; Eric J G Sijbrands; Felix W M de Rooij; Mark Lebwohl; Hetanshi Naik; Colin R Goding; J H Paul Wilson; Robert J Desnick
Journal:  N Engl J Med       Date:  2015-07-02       Impact factor: 91.245

8.  Porphyria cutanea tarda and hepatitis C virus: a case-control study and meta-analysis of the literature.

Authors:  T Y Chuang; R Brashear; C Lewis
Journal:  J Am Acad Dermatol       Date:  1999-07       Impact factor: 11.527

9.  The very first description of a patient with hepatoerythropoietic porphyria in Argentina. Biochemical and molecular studies.

Authors:  B X Granata; V E Parera; V A Melito; M J Teijo; A M del C Batlle; M V Rossetti
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2009-02-16       Impact factor: 1.770

Review 10.  [Congenital erythropoietic porphyria].

Authors:  K Tanigawa; N Takamura; S Yamashita
Journal:  Nihon Rinsho       Date:  1995-06
View more
  22 in total

1.  Porphyria cutanea tarda presenting as milia and blisters.

Authors:  Long Hoai Nguyen; Karima Khamisa
Journal:  CMAJ       Date:  2018-05-22       Impact factor: 8.262

Review 2.  Psychiatric Aspects of Acute Porphyria: a Comprehensive Review.

Authors:  Laura Duque-Serrano; Liliana Patarroyo-Rodriguez; Dorothy Gotlib; Juan C Molano-Eslava
Journal:  Curr Psychiatry Rep       Date:  2018-02-02       Impact factor: 5.285

Review 3.  Hepatic porphyria: A narrative review.

Authors:  Sumant Arora; Steven Young; Sudha Kodali; Ashwani K Singal
Journal:  Indian J Gastroenterol       Date:  2016-10-31

Review 4.  Psychological Aspect and Quality of Life in Porphyrias: A Review.

Authors:  Granata Francesca; Annamaria Nicolli; Alessia Colaiocco; Elena Di Pierro; Giovanna Graziadei
Journal:  Diagnostics (Basel)       Date:  2022-05-10

Review 5.  Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran.

Authors:  Pedro Renato de Paula Brandão; Simoneide S Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

6.  Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.

Authors:  Paolo Ventura; Herbert L Bonkovsky; Laurent Gouya; Paula Aguilera-Peiró; D Montgomery Bissell; Penelope E Stein; Manisha Balwani; D Karl E Anderson; Charles Parker; David J Kuter; Susana Monroy; Jeeyoung Oh; Bruce Ritchie; John J Ko; Zhaowei Hua; Marianne T Sweetser; Eliane Sardh
Journal:  Liver Int       Date:  2021-11-16       Impact factor: 8.754

7.  Neonatal hemolytic anemia does not always indicate thalassemia: a case report.

Authors:  Arwa A Al-Harazi; Bilguis M Al-Eryani; Butheinah A Al-Sharafi
Journal:  BMC Res Notes       Date:  2017-09-12

8.  Clinical, Biochemical Characteristics and Hospital Outcome of Acute Intermittent Porphyria Patients: A Descriptive Study from North India.

Authors:  Susheel Kumar; Ashish Bhalla; Navneet Sharma; Deba Prasad Dhibar; Savita Kumari; Subhash Varma
Journal:  Ann Indian Acad Neurol       Date:  2017 Jul-Sep       Impact factor: 1.383

Review 9.  Unraveling the Role of Heme in Neurodegeneration.

Authors:  Deborah Chiabrando; Veronica Fiorito; Sara Petrillo; Emanuela Tolosano
Journal:  Front Neurosci       Date:  2018-10-09       Impact factor: 4.677

Review 10.  The Skin in Celiac Disease Patients: The Other Side of the Coin.

Authors:  Ludovico Abenavoli; Stefano Dastoli; Luigi Bennardo; Luigi Boccuto; Maria Passante; Martina Silvestri; Ilaria Proietti; Concetta Potenza; Francesco Luzza; Steven Paul Nisticò
Journal:  Medicina (Kaunas)       Date:  2019-09-09       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.